INTERMITTENT ANDROGEN DEPRIVATION AS SECONDARY THERAPY FOR BIOCHEMICAL RECURRENCE OF LOCALIZED PROSTATE CANCER

被引：1
|
作者：
Sanchez-Salas, R. E. [1 ]
Prapotnich, D. [1 ]
Secin, F. P. [2 ]
Favaretto, R. [1 ]
Flamand, V [1 ]
Rozet, F. [1 ]
Galiano, M. [1 ]
Barret, E. [1 ]
Cathelineau, X. [1 ]
机构：
[1] Inst Montsouris, Dept Urol, Paris, France
[2] CEMIC, Dept Urol, Buenos Aires, DF, Argentina
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2011年 / 10卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(11)60222-4
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：91 / 92
页数：2
相关论文
共 50 条
  • [41] Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer Reply
    D'Amico, Anthony V.
    Chen, Ming-Hui
    Kantoff, Philip W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (10): : 1055 - 1056
  • [42] Radiotherapy plus androgen deprivation therapy better for localized prostate cancer
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2014, 75 (05) : 249 - 249
  • [43] The Use of Androgen Deprivation Therapy in Combination With Radiation for Localized Prostate Cancer
    Anderson, Eric M.
    Mcbride, Sean M.
    FRONTIERS IN UROLOGY, 2022, 2
  • [44] Outcomes of androgen deprivation as sole therapy for localized prostate cancer.
    Janoff, D
    Mongoue-Tchokote, S
    Peterson, C
    Parra, RO
    Peters, L
    Park, Y
    Beer, TM
    Mori, M
    Garzotto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 413S - 413S
  • [45] HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.
    Hearn, Jason W. D.
    Xie, Wanling
    Nakabayashi, Mari
    Almassi, Nima
    Reichard, Chad A.
    Pomerantz, Mark
    Kantoff, Philip W.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Intermittent androgen deprivation as rescue treatment for radiotherapy biochemical failures in the prostate cancer patients
    Villa, S
    Gramaglia, A
    Scorsetti, M
    Bedini, N
    Cerreta, V
    Tana, S
    TUMORI, 2001, 87 (04) : S138 - S139
  • [47] Intermittent Androgen Deprivation with the GnRH Antagonist Degarelix in Men with Biochemical Relapse of Prostate Cancer
    Crawford, E. David
    Shore, Neal
    Higano, Celestia S.
    Neijber, Anders
    Yankov, Vladimir
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (12) : 6 - 13
  • [48] Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
    Klotz, L.
    Toren, P.
    CURRENT ONCOLOGY, 2012, 19 : S13 - S21
  • [49] Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer
    Sciarra, A
    Di Chiro, C
    Di Silverio, F
    WORLD JOURNAL OF UROLOGY, 2000, 18 (06) : 392 - 400
  • [50] Testosterone kinetics in the first cycle of intermittent androgen deprivation (IAD) for men with localized or biochemical relapse (BR) of prostate cancer (PC)
    Gulati, R.
    Yu, E. Y.
    Telesca, D.
    Jiang, P.
    Montgomery, R. B.
    Tam, S.
    Russell, K. J.
    Nelson, P. S.
    Etzioni, R. B.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345